Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China

AIMS: This study was to determine the cost‐effectiveness of dapagliflozin in heart failure with reduced ejection fraction (HFrEF) patients in China from a perspective of health care payers. METHODS AND RESULTS: We built a Markov model to perform a cost‐effectiveness analysis comparing standard treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Younan, Zhang, Rongcheng, An, Tao, Zhao, Xinke, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754897/
https://www.ncbi.nlm.nih.gov/pubmed/33107212
http://dx.doi.org/10.1002/ehf2.12844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754897/
https://www.ncbi.nlm.nih.gov/pubmed/33107212
http://dx.doi.org/10.1002/ehf2.12844

Ejemplares similares